文献速递真菌感染医院感染防控

造血细胞移植后肺侵袭性霉菌感染诊断前后血浆微生物游离DNA的连续定量检测

Serial Quantitation of Plasma Microbial Cell-Free DNA Before and After Diagnosis of Pulmonary Invasive Mold Infections After Hematopoietic Cell Transplant.
PubMed 文献 · J Infect Dis · 2024-01-01

该研究回顾性检测了35例造血细胞移植受者39次肺侵袭性霉菌感染诊断前后4周内的血浆微生物游离DNA测序结果。致病霉菌在临床诊断前第1、2、3、4周采集的样本中检出率分别为38%、26%、11%和0%。在非曲霉菌感染中,诊断3天内采集样本的中位mcfDNA浓度在伴肺外播散者中高于无肺外播散者,且mcfDNA浓度>4.0 log10 mpm的患者均在诊断后42天内死亡。

要点

  • 血浆mcfDNA-Seq可在肺侵袭性霉菌感染临床诊断前最多3周检出致病霉菌。
  • 非曲霉菌感染中,诊断3天内mcfDNA浓度在伴肺外播散者中高于无肺外播散者。
  • 非曲霉菌感染中mcfDNA浓度>4.0 log10 mpm的患者均在诊断后42天内死亡。

核心结论

  • 血浆mcfDNA-Seq可在肺侵袭性霉菌感染临床诊断前最多3周识别致病霉菌。
  • 血浆mcfDNA浓度可能与非曲霉菌侵袭性霉菌感染的肺外播散和死亡相关。

研究设计与样本

  • 回顾性检测造血细胞移植受者中经mcfDNA-Seq在临床诊断14天内检出至少1种霉菌的肺侵袭性霉菌感染病例。
  • 纳入35例造血细胞移植受者共39次侵袭性霉菌感染,其中曲霉菌感染16次、非曲霉菌感染23次。
  • 评估侵袭性霉菌感染诊断前最多4周至诊断后4周采集的血浆样本,采用mcfDNA-Seq检测。

主要发现

  • 临床诊断前第1周、第2周、第3周和第4周采集的样本中致病霉菌检出率分别为38%、26%、11%和0%。
  • 非曲霉菌感染中,诊断3天内采集样本的中位mcfDNA浓度在伴肺外播散者中为4.3 log10 mpm,无肺外播散者为3.3 log10 mpm(P = .02)。
  • 非曲霉菌感染中mcfDNA浓度>4.0 log10 mpm的患者均在临床诊断后42天内死亡(8/8)。

关键数值与推荐

  • 致病霉菌检出率:诊断前第1周38%、第2周26%、第3周11%、第4周0%。
  • 非曲霉菌感染诊断3天内中位mcfDNA浓度:伴肺外播散者4.3 log10 mpm vs 无肺外播散者3.3 log10 mpm(P = .02)。
  • 非曲霉菌感染中mcfDNA浓度>4.0 log10 mpm者临床诊断后42天内死亡比例为8/8。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Plasma microbial cell-free DNA sequencing (mcfDNA-Seq) is a noninvasive test for microbial diagnosis of invasive mold infection (IMI). The utility of mcfDNA-Seq for predicting IMI onset and the clinical implications of mcfDNA concentrations are unknown. METHODS: We retrospectively tested plasma from hematopoietic cell transplant (HCT) recipients with pulmonary IMI and ≥1 mold identified by mcfDNA-Seq in plasma collected within 14 days of clinical diagnosis. Samples collected from up to 4 weeks before and 4 weeks after IMI diagnosis were evaluated using mcfDNA-Seq. RESULTS: Thirty-five HCT recipients with 39 IMIs (16 Aspergillus and 23 non-Aspergillus infections) were included. Pathogenic molds were detected in 38%, 26%, 11%, and 0% of samples collected during the first, second, third, and fourth week before clinical diagnosis, respectively. In non-Aspergillus infections, median mcfDNA concentrations in samples collected within 3 days of clinical diagnosis were higher in infections with versus without extrapulmonary spread (4.3 vs 3.3 log10 molecules per microliter [mpm], P = .02), and all patients (8/8) with mcfDNA concentrations >4.0 log10 mpm died within 42 days after clinical diagnosis. CONCLUSIONS: Plasma mcfDNA-Seq can identify pathogenic molds up to 3 weeks before clinical diagnosis of pulmonary IMI. Plasma mcfDNA concentrations may correlate with extrapulmonary spread and mortality in non-Aspergillus IMI.

来源:J Infect Dis,查看原文。版权归原作者所有。

引用

  1. Heldman MR, Ahmed AA, Liu W, et al. Serial Quantitation of Plasma Microbial Cell-Free DNA Before and After Diagnosis of Pulmonary Invasive Mold Infections After Hematopoietic Cell Transplant. J Infect Dis. 2024. PMID: 37405403. doi:10.1093/infdis/jiad255

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。